New hope for PAH patients: experimental drug enters clinical testing
NCT ID NCT07318597
Summary
This study is testing an investigational drug called REGN13335 in adults with pulmonary arterial hypertension (PAH). Participants will continue taking their standard PAH medications while receiving either REGN13335 or a placebo to see if the new drug is safe and helps improve heart and lung function. The main goal is to see if the drug reduces resistance in the blood vessels of the lungs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.